Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central XXXX (CRVO) with @entity1103 : a pilot study.

@entity1 @entity2994 @entity4 @entity384 @entity1103 @entity5861
PURPOSE: To evaluate the effect of single-dose intravitreal bevacizumab followed by panretinal and macular grid laser, early in the course of central @entity2994 (CRVO). METHODS: It is a prospective, non-randomized, interventional study of nine eyes of nine @entity1 with <10 days origin of CRVO who received 2.5 mg (0.1 ml) intravitreal bevacizumab, followed 3 weeks later by panretinal and macular grid photocoagulation. Its effect on visual acuity and anatomical features of CRVO were studied. RESULTS: Nine eyes of nine @entity1 (male : female = 8 : 1, mean age 54 years), with <10 days (average 2.67 days) onset of CRVO, received intravitreal bevacizumab within 7 days of presentation (average 3.1 days) followed 3 weeks later by panretinal with macular grid laser. Presenting mean baseline visual acuity was 20/320 (1.2 logarithm of the minimum angle of resolution (LOGMAR) units). All the @entity1 showed rapid improvement in the form of rapid clearance of @entity5861 , decreased @entity4 and @entity384 , and tortuosity. Mean final visual acuity was 20/63 (0.5 LOGMAR units). No @entity1 showed conversion from non-ischemic to ischaemic CRVO, recurrence of @entity1103 , and disc collateral formation. CONCLUSION: Early intravitreal bevacizumab followed by panretinal and macular grid laser may provide visually and anatomically favourable results in a case of CRVO. It may also obviate the need for repeated injection. It requires a large randomized study to substantiate the results.
